PEDIATRIC HEMATOLOGY AND ONCOLOGY

Scope & Guideline

Fostering dialogue in the realm of child health and treatment.

Introduction

Welcome to the PEDIATRIC HEMATOLOGY AND ONCOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of PEDIATRIC HEMATOLOGY AND ONCOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0888-0018
PublisherTAYLOR & FRANCIS INC
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1984 to 2024
AbbreviationPEDIATR HEMAT ONCOL / Pediatr. Hematol. Oncol.
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106

Aims and Scopes

Pediatric Hematology and Oncology focuses on the comprehensive understanding and treatment of blood disorders and cancers in children. The journal aims to disseminate innovative research, clinical findings, and reviews that improve the knowledge and practices within this specialized field.
  1. Pediatric Hematology:
    Research on various hematological disorders affecting children, including anemia, sickle cell disease, and hemophilia, with an emphasis on pathophysiology, treatment modalities, and long-term outcomes.
  2. Oncological Studies:
    Focused studies on pediatric cancers, including leukemia, lymphoma, and solid tumors, exploring diagnosis, treatment strategies, clinical trials, and survivorship.
  3. Transplantation and Cellular Therapies:
    Investigation into hematopoietic stem cell transplantation and other cellular therapies as treatment options for pediatric patients with severe hematological malignancies.
  4. Genetic and Molecular Research:
    Studies examining the genetic underpinnings of pediatric diseases, including genetic disorders, cancer predisposition, and the role of molecular markers in treatment responses.
  5. Supportive Care and Quality of Life:
    Research addressing supportive care measures, psychosocial aspects, and quality of life outcomes for pediatric patients and their families throughout treatment and survivorship.
  6. International Health and Disparities:
    Exploration of the challenges and outcomes of pediatric hematology and oncology in low- and middle-income countries, focusing on access to care and treatment disparities.
The journal has seen a rise in interest in several innovative and critical areas of research that reflect the evolving landscape of pediatric hematology and oncology. These emerging themes are crucial in shaping future research directions and clinical practices.
  1. Precision Medicine and Genetic Testing:
    An increasing number of papers focus on the application of genetic testing and precision medicine approaches to tailor treatments for pediatric patients, indicating a significant trend towards personalized healthcare.
  2. Impact of COVID-19 on Pediatric Patients:
    Research examining the effects of the COVID-19 pandemic on pediatric hematology and oncology patients is on the rise, highlighting the need for understanding how global health crises affect care delivery and patient outcomes.
  3. Innovative Supportive Care Strategies:
    Emerging studies are focusing on supportive care interventions, including psychosocial support and palliative care, which are crucial for improving the quality of life for pediatric patients and their families.
  4. Long-Term Outcomes and Survivorship:
    There is a growing emphasis on the long-term health outcomes and survivorship issues faced by pediatric cancer survivors, reflecting a shift towards recognizing the importance of post-treatment quality of life.
  5. International Collaborative Research:
    An increase in multicenter and international studies indicates a trend towards collaborative research efforts, aiming to address global disparities in pediatric cancer care and outcomes.

Declining or Waning

While certain research areas continue to thrive, others appear to be declining in prominence within the journal. This may reflect shifting priorities in pediatric hematology and oncology or changes in research funding and interest.
  1. Traditional Chemotherapy Approaches:
    There seems to be a decrease in studies focusing solely on conventional chemotherapy regimens, as newer targeted therapies and immunotherapies gain more attention in the treatment of pediatric cancers.
  2. Single-Center Studies:
    A noticeable decline in the publication of single-center studies suggests a shift towards multicenter collaborations that provide broader data and insights into treatment outcomes.
  3. Basic Science and Laboratory Studies:
    Research papers focusing on basic science and laboratory methodologies appear to be waning as clinical applications and translational research take precedence, highlighting a move towards practical and immediate clinical relevance.

Similar Journals

ANNALS OF HEMATOLOGY

Elevating knowledge with impactful research and reviews.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

Journal of Adolescent and Young Adult Oncology

Transforming Cancer Care for Adolescents and Young Adults
Publisher: MARY ANN LIEBERT, INCISSN: 2156-5333Frequency: 6 issues/year

The Journal of Adolescent and Young Adult Oncology, published by MARY ANN LIEBERT, INC, is a premier peer-reviewed journal dedicated to enhancing the understanding and treatment of cancers in adolescents and young adults. With an ISSN of 2156-5333 and an E-ISSN of 2156-535X, this journal specializes in providing vital insights into the unique challenges faced by younger cancer patients, promoting research and clinical best practices in this underrepresented population. The journal features a commendable ranking in the Q2 quartile for Oncology and Q1 quartile for Pediatrics, Perinatology, and Child Health—highlighting its impact and relevance in both fields. Its Scopus rankings also reflect a strong standing; positioned at Rank #107/330 in Pediatrics and Rank #225/404 in Oncology. While the journal operates under a subscription-based model, it aims to disseminate crucial research findings and innovative treatments through its engaging content that serves as an invaluable resource for researchers, clinicians, and students alike. Since its inception in 2014, the journal has been at the forefront of addressing the pressing issues pertinent to young cancer patients, making it a vital outlet for groundbreaking studies and clinical advancements within this critical area of healthcare.

UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi

Transforming research into impactful clinical practices.
Publisher: AKAD DOKTORLAR YAYINEVIISSN: 1306-133XFrequency: 4 issues/year

UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi, published by AKAD DOKTORLAR YAYINEVI, is a pivotal journal in the fields of hematology and oncology, catering to an international audience of researchers, clinicians, and students. Since its inception in 2005, the journal has committed to disseminating high-quality, peer-reviewed research, highlighting advancements and challenges in the diagnosis and treatment of hematological and oncological disorders. Registered under ISSN 1306-133X, it serves as a significant platform for scholarly discourse, despite its recent categorization in the Q4 quartile for both hematology and oncology—indicating opportunities for growth and contribution within the scientific community. While currently not Open Access, the journal's indexed contribution to Scopus ranks it within the 12th and 17th percentiles in the domains of hematology and oncology respectively, reflecting its emerging presence within the academic landscape. As it approaches its convergence point in 2024, UHOD strives to elevate its influence, providing invaluable insights and fostering collaborations in the ongoing fight against blood disorders and cancer.

Egyptian Journal of Haematology

Navigating the Future of Hematology with Rigorous Research
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Hematology-American Society of Hematology Education Program

Navigating the Future of Hematology Together
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Blood Cancer Discovery

Pioneering Discoveries for a Cancer-Free Tomorrow
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

EUROPEAN JOURNAL OF HAEMATOLOGY

Innovative Insights into Blood Health and Disease
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Blood and Lymphatic Cancer-Targets and Therapy

Illuminating the Path to Effective Cancer Interventions
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-9889Frequency: 1 issue/year

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Hematology Transfusion and Cell Therapy

Elevating standards in cell therapy and transfusion science.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Therapeutic Advances in Hematology

Elevating therapeutic practices in hematology.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.